ClinicalTrials.gg
CompletedNCT04519827CHARMUpdated Dec 8, 2023

A Hypoallergenicity Study on a New Rice-Based Hydrolysate Formula

An interventional study of New Rice-based hydrolysate and Amino Acid-based infant formula in Allergy;Food, sponsored by Dr. Schär AG / SPA. Completed at 4 sites in 2 countries. Open to participants aged Up to 10 Years. Per ClinicalTrials.gov, last updated 2023-12-08.

Primary conditionMilk HypersensitivityRegistry: Food HypersensitivityReclassifiedWhy we changed it
Registry
Food Hypersensitivity — the first condition term the registry derived for this study.
ClinicalTrials.gg
Milk Hypersensitivity
Why
  1. The study's title name Milk Hypersensitivity, a narrower term within Food Hypersensitivity.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Dr. Schär AG / SPA · Not applicable, Interventional, and Other

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
39
Allocation
Randomized
Ages
Up to 10 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 29 studies in Milk Hypersensitivity with a site in Italy — 1 open to participants now, 2 under way, none of them phase 3. Milk Hypersensitivity · Italy.

Enrollment
12th of 21
39 · median 41
Started
2020
with 1 other
No phase
17 of 29
1 open now
Registered
24th of 29
by date
Lead sponsor
1 of 29
Dr. Schär AG / SPA

Among the 29 studies in Milk Hypersensitivity with a site in Italy, this one is the 12th largest by enrollment of the 21 interventional ones that give a count, is one of 2 that started in 2020, is one of 17 with no phase, and was the 24th registered.

Milk Hypersensitivity

147 studies on the registry are indexed under Milk Hypersensitivity; 26 are open to participants now.

Browse Milk Hypersensitivity studies →

Open to participants now

1 of the 29 studies in Milk Hypersensitivity with a site in Italy is open now. Recruiting first, the newest first:

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 16 Milk Hypersensitivity studies recruiting now, 1 (6%) sets no upper age limit and 15 (94%) stop at 75 or younger; 15 take children under 18; 1 takes healthy volunteers.

This study: Up to 10 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies in Milk Hypersensitivity with a site in Italy, or all of them as a file.
02

Study summary

Cow's Milk Allergy (CMA) affects between 2-3% of young children but its severity varies between regions/countries. While the long-term prognosis for CMA is good, with the majority (80-90%) of children outgrowing their allergy by around 3-5 years. Breast feeding is the most optimal form of feeding for all infants, regardless of their condition, and in those with CMA maternal dairy exclusion is recommended as first line treatment. In non-breast fed or mixed feeding, a hypoallergenic milk substitute is recommended for young infants. The AAP and other societies such as EAACI and ESPGHAN considers a formula to be 'hypoallergenic' if at least 90% of children with documented CMA tolerate it, with a 95% CI, under double-blind, placebo-controlled conditions.This equates to at least 29 children who should tolerate the product following blind and open challenge.

Read the detailed description

A prospective, multi-centre double blind randomised placebo-controlled study to demonstrate the safety and tolerance of a new rice-based hydrolysate in children with diagnosed Cow's Milk Allergy (CMA). The test product being a new milk substitute hydrolysed rice-based formula with new ingredient. The results will satisfy the safety requirement when tolerated by 90% of children with proven CMA, with a confidence of 95%. New, and previously diagnosed children with confirmed CMA who meet the inclusion criteria will be eligible to participate in the study. Those included in the intervention phase will have IgE testing and an oral food challenge (OFC) to test and placebo products, in a randomised double-blind design. Children with a negative reaction to both test and placebo products will receive the test product for a period of 7 days (open challenge).

03

Conditions studied

  • Allergy;Food

Browse trials for

Keywords

  • Cow's Milk Protein Allergy (CMPA)
  • Cow's Milk Allergy (CMA)
  • CHILDREN
04

In context

Milk Hypersensitivity Reclassified

147 studies on the registry are indexed under Milk Hypersensitivity; 26 are open to participants now.

This study's enrollment of 39 is below the median of 68 across 95 interventional studies indexed under Milk Hypersensitivity.

Browse Milk Hypersensitivity studies →

Lead sponsor

Dr. Schär AG / SPA is the lead sponsor of 9 studies on the registry; 1 is open to participants now.

Compared within Milk Hypersensitivity, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Food Hypersensitivity. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
Up to 10 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Children \<10 yrs of age
  2. Proven IgE-mediated CMA
  3. >2500g at birth
  4. > 37 weeks gestation
  5. Written provided by parent(s)/guardian

Exclusion criteria

Exclusion Criteria:

  1. Infants/children with severe concurrent illness (other than food allergy/CMA)
  2. Investigator's uncertainty about the willingness or ability of the subject to comply with the protocol requirements.
  3. Participation in other studies involving use of milk replacement products designed to treat/manage CMA within two weeks prior to entry into this study
  4. Current participation in OIT to Cow's Milk
  5. Diagnosis of anaphylaxis to Cow's Milk
  6. Diagnosis of rice allergy
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

06

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
39 participants (actual)

Study arms

  • Experimental
    New Rice-based hydrolysate

    The TEST formula is a new Rice-based hydrolysate with new ingredient.

    Other: New Rice-based hydrolysate

  • Placebo comparator
    Amino-acid based formula

    The PLACEBO is an Amino-acid based formula.

    Other: Amino Acid-based infant formula

Interventions

  • OtherNew Rice-based hydrolysate

    A rice-based hydrolysed infant formula with new ingredient

  • OtherAmino Acid-based infant formula

    An amino acid-based infant formula

07

What researchers measure

Primary outcomes

  1. Hypoallergenicity

    90% of children tolerate the TEST formula with a 95% CI - using the double blind placebo controlled food challenge and open challenge (Test vs. placebo).

    Time frame: 7 days open challenge

08

Study locations

4 sites
  • Meyer Children's Hospital
    Florence, 50139, Italy
  • Spett.le Universita degli Studi di Napoli ''Federico II''
    Napoli, 80131, Italy
  • Hospital Infantile Regina Margherita.
    Turin, 10126, Italy
  • Hospital Sant Joan de Déu Barcelona 2020,
    Barcelona, 08950 Esplugues de Llobregat,, Spain
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2020 to primary completion in Nov 2023, 42 months.

Of 34 interventional studies with no phase under Milk Hypersensitivity, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 48. This study's 42 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 17, 2020
First posted
Aug 20, 2020
StartActual
May 21, 2020
Primary completionActual
Nov 29, 2023
CompletionActual
Nov 29, 2023
Last update
Dec 8, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 8, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04519827
Lead sponsor
Dr. Schär AG / SPA
Responsible party
Sponsor
First posted
Aug 20, 2020
Start date
May 21, 2020
Primary completion
Nov 29, 2023
Completion
Nov 29, 2023
Last update
Dec 8, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion